elahere

Generic: mirvetuximab soravtansine-gynx

elahere: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
ImmunoGen, Inc. (IMGN)Approved

FDA Decisions

Approval1 INDICATIONS AND USAGE ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )]. ELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment o(IMGN)

Frequently asked questions

Who is developing elahere?

elahere is being developed by ImmunoGen, Inc..

What is elahere's latest FDA decision?

The most recent tracked FDA decision for elahere is Approval for 1 INDICATIONS AND USAGE ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )]. ELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment o, dated November 14, 2022.

Get deeper analysis on elahere

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    elahere — Drug Pipeline, Trials & FDA Status | BioSniper